Zelluna ASA (ZLNA) NOK1

Zelluna ASA, formerly Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company develops cell therapies for the treatment of cancer patients. Zelluna ASA deals with eliminate solid cancers by unleashing thel elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The Company provides benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that has the potential to be both safe and potent. Zelluna ASA operates worldwide.